María Belén Sanz, Fernando Pasteran, Juan Manuel de Mendieta, Florencia Brunetti, Ezequiel Albornoz, Melina Rapoport, Celeste Lucero, Laura Errecalde, Maria Rosa Nuñez, Renata Monge, Magdalena Pennini, Pablo Power, Alejandra Corso, Sonia A Gomez
Ceftazidime-avibactam (CZA) therapy has significantly improved survival rates for patients infected by carbapenem-resistant bacteria, including KPC producers. However, resistance to CZA is a growing concern, attributed to multiple mechanisms. In this study, we characterized four clinical CZA-resistant Klebsiella pneumoniae isolates obtained between July 2019 and December 2020. These isolates expressed novel allelic variants of bla KPC-2 resulting from changes in hotspots of the mature protein, particularly in loops surrounding the active site of KPC...
February 6, 2024: Microbiology Spectrum